Xing Wenqian, Li Ting, Yang Guangze, Wu Shuqin, Pang Bailu, Xu Yufang, Qian Xuhong, Zhu Weiping
State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China; Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.
State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.
Acta Biomater. 2025 Jan 15;192:353-365. doi: 10.1016/j.actbio.2024.11.035. Epub 2024 Nov 26.
Photothermal therapy (PTT) is a promising treatment strategy for malignant tumors. Photothermal agents which can achieve efficient photothermal conversion in the NIR-II region plays crucial roles in this remedy. Here, we report one type of thermo-responsive gold nanorod vesicles USGRV-17-AAG for combined NIR-II photothermal therapy and chemotherapy of solid tumors. The nanovesicles are formed by self-assembly of gold nanorods modified with amphiphilic polymers (PEG-b-PS) and UCST-type polymers (P(AAm-co-AN)), and are loaded with the heat shock protein inhibitor 17-AAG. Upon 1064 nm laser irradiation, USGRV-17-AAG exhibits a high photothermal conversion efficiency (65.1 %) and thus can achieve temperature responsive release of tanespimycin (17-AAG), an inhibitor of HSP90. The combination of NIR-II photothermal therapy and chemotherapy can effectively eliminate tumor cells and inhibit the expression of HSP90. Intravenous injection of USGRV-17-AAG followed by 1064 nm laser irradiation revealed efficacious tumor ablation of tumor-bearing mice, with a tumor growth inhibition rate of 98.86 %. Therefore, USGRV-17-AAG can produce efficient anti-tumor effects and provides an alternative approach to the treatment of malignant tumors. STATEMENT OF SIGNIFICANCE: Photothermal conversion agents (PTAs) based on the near-infrared II (NIR-II) window are currently attracting significant attention for their promising development and diverse applications. In this study, thermosensitive drug-loaded nanovesicles, USGRV-17-AAG, were designed to enable NIR-II photothermal therapy in combination with chemotherapy. These nanovesicles were loaded with the heat shock protein 90 (HSP90) inhibitor 17-AAG, which effectively inhibits HSP90 expression and enhances the therapeutic efficacy of photothermal treatment. Additionally, USGRV-17-AAG exhibited efficient photothermal conversion (65.1 %) under 1064 nm laser irradiation and enabled temperature-responsive drug release through the action of surface-modified upper critical solution temperature (UCST) polymers. This nanocarrier, with enhanced NIR-II photothermal therapy, might offer a promising solution for anti-tumor treatment.
光热疗法(PTT)是一种很有前景的恶性肿瘤治疗策略。能够在近红外二区(NIR-II)实现高效光热转换的光热剂在这种治疗方法中起着关键作用。在此,我们报道了一种用于实体瘤的近红外二区光热联合化疗的热响应性金纳米棒囊泡USGRV-17-AAG。该纳米囊泡由两亲性聚合物(PEG-b-PS)和最低临界溶液温度(UCST)型聚合物(P(AAm-co-AN))修饰的金纳米棒自组装形成,并负载有热休克蛋白抑制剂17-AAG。在1064nm激光照射下,USGRV-17-AAG表现出高的光热转换效率(65.1%),从而能实现HSP90抑制剂坦螺旋霉素(17-AAG)的温度响应释放。近红外二区光热疗法与化疗相结合可有效消除肿瘤细胞并抑制HSP90的表达。静脉注射USGRV-17-AAG后进行1064nm激光照射,显示对荷瘤小鼠有有效的肿瘤消融作用,肿瘤生长抑制率为98.86%。因此,USGRV-17-AAG可产生高效的抗肿瘤作用,并为恶性肿瘤的治疗提供了一种替代方法。
基于近红外二区(NIR-II)窗口的光热转换剂(PTA)因其有前景的发展和多样的应用目前正受到广泛关注。在本研究中,设计了热敏载药纳米囊泡USGRV-17-AAG以实现近红外二区光热疗法与化疗相结合。这些纳米囊泡负载有热休克蛋白90(HSP90)抑制剂17-AAG,其可有效抑制HSP90表达并增强光热治疗的疗效。此外,USGRV-17-AAG在1064nm激光照射下表现出高效的光热转换(65.1%),并通过表面修饰的最低临界溶液温度(UCST)聚合物的作用实现温度响应性药物释放。这种具有增强的近红外二区光热疗法的纳米载体可能为抗肿瘤治疗提供一种有前景的解决方案。